A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

NCT01192906 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

624

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Placebo
DRUG: bitopertin [RO4917838]
DRUG: bitopertin [RO4917838]

Sponsor

Hoffmann-La Roche